Clinical Trial Update: A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating nimotuzumab for recurrent or metastatic cervical cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: National Institute of Cancerología | Conditions: Uterine Cervical Cancer | Phase 1, Phase 2 | Status: COMPLETED